{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:41:37Z","timestamp":1789188097524,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015988","name":"Norman Beischer Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015988","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022449","name":"UNC Department of Obstetrics and Gynecology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004477","name":"Universiteit Stellenbosch","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004477","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jpba.2023.115633","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T11:30:11Z","timestamp":1692012611000},"page":"115633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["An LC-MS\/MS method for the simultaneous quantitation of sulfasalazine and sulfapyridine in human placenta"],"prefix":"10.1016","volume":"235","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6074-2362","authenticated-orcid":false,"given":"Vanessa","family":"Louw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Brownfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-8964","authenticated-orcid":false,"given":"Catherine","family":"Cluver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1815-5150","authenticated-orcid":false,"given":"Eric","family":"Decloedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1542-4976","authenticated-orcid":false,"given":"Tracy","family":"Kellermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115633_bib1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ebiom.2019.02.013","article-title":"Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction","volume":"41","author":"Brownfoot","year":"2019","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jpba.2023.115633_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(20)32335-7","article-title":"Pre-eclampsia","volume":"398","author":"Chappell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2023.115633_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejogrb.2013.05.005","article-title":"Global and regional estimates of preeclampsia and eclampsia: a systematic review","volume":"170","author":"Abalos","year":"2013","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.jpba.2023.115633_bib4","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1161\/HYPERTENSIONAHA.111.00226","article-title":"Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension","volume":"61","author":"Bauer","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.jpba.2023.115633_bib5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(05)17987-2","article-title":"Pre-eclampsia","volume":"365","author":"Sibai","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2023.115633_bib6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.preghy.2020.07.013","article-title":"Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia","volume":"22","author":"Binder","year":"2020","journal-title":"Pregnancy Hypertens."},{"key":"10.1016\/j.jpba.2023.115633_bib7","article-title":"A double blind, randomised, placebo-controlled trial to evaluate the efficacy of metformin to treat preterm pre-eclampsia (PI2 trial): study protocol","volume":"9","author":"Cluver","year":"2019","journal-title":"Br. Med J."},{"key":"10.1016\/j.jpba.2023.115633_bib8","article-title":"Double blind, randomised, placebo-controlled trial to evaluate the efficacy of esomeprazole to treat early onset pre-eclampsia (PIE Trial): a study protocol","author":"Cluver","year":"2015","journal-title":"Br. Med J."},{"key":"10.1016\/j.jpba.2023.115633_bib9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1161\/HYPERTENSIONAHA.117.10681","article-title":"AT1-AA (angiotensin II type 1 receptor agonistic autoantibody) blockade prevents preeclamptic symptoms in placental ischemic rats","volume":"71","author":"Cunningham","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jpba.2023.115633_bib10","first-page":"181","article-title":"Diagnosis and management of gestational hypertension and preeclampsia","volume":"102","author":"Sibai","year":"2003","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jpba.2023.115633_bib11","doi-asserted-by":"crossref","unstructured":"Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy, Am J. Obstet. Gynecol., 183, 2000. \u3008https:\/\/doi.org\/10.1067\/mob.2000.107928\u3009.","DOI":"10.1016\/S0002-9378(00)40820-3"},{"key":"10.1016\/j.jpba.2023.115633_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.placenta.2020.04.010","article-title":"Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia","volume":"95","author":"Brownfoot","year":"2020","journal-title":"Placenta"},{"key":"10.1016\/j.jpba.2023.115633_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1161\/HYPERTENSIONAHA.116.08408","article-title":"Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction","volume":"69","author":"Onda","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.jpba.2023.115633_bib14","article-title":"Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial","volume":"374","author":"Cluver","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jpba.2023.115633_bib15","doi-asserted-by":"crossref","first-page":"356.e1","DOI":"10.1016\/j.ajog.2015.12.019","article-title":"Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction","volume":"214","author":"Brownfoot","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.jpba.2023.115633_bib16","doi-asserted-by":"crossref","DOI":"10.1186\/s12884-016-0902-3","article-title":"Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta","volume":"16","author":"Brownfoot","year":"2016","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.jpba.2023.115633_bib17","doi-asserted-by":"crossref","first-page":"720.e1","DOI":"10.1016\/j.ajog.2015.12.038","article-title":"Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial","volume":"214","author":"Costantine","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.jpba.2023.115633_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.placenta.2019.09.004","article-title":"Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling","volume":"87","author":"Hastie","year":"2019","journal-title":"Placenta"},{"key":"10.1016\/j.jpba.2023.115633_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.placenta.2020.08.022","article-title":"Novel approaches to combat preeclampsia: from new drugs to innovative delivery","volume":"102","author":"de Alwis","year":"2020","journal-title":"Placenta"},{"key":"10.1016\/j.jpba.2023.115633_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jchromb.2010.12.034","article-title":"Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography\/tandem mass spectrometry and its application to a pharmacokinetic study","volume":"879","author":"Gu","year":"2011","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2023.115633_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26041179","article-title":"Quantification and metabolite identification of sulfasalazine in mouse brain and plasma using quadrupole-time-of-flight mass spectrometry","volume":"26","author":"Choi","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.jpba.2023.115633_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0378-4347(87)80045-2","article-title":"Rapid method for the determination of either plasma sulphapyridine or sulphamethoxazole and their acetyl metabolites using high-performance liquid chromatography","volume":"414","author":"Astbury","year":"1987","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.jpba.2023.115633_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0731-7085(88)80035-9","article-title":"A modified reversed-phase high-performance liquid chromatographic method for the determination of plasma sulphasalazine concentrations","volume":"6","author":"Astbury","year":"1988","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115633_bib24","doi-asserted-by":"crossref","DOI":"10.4172\/2153-2435.1000288","article-title":"Bioanalytical method validation and its pharmaceutical application: a review","volume":"05","author":"Sonawane","year":"2014","journal-title":"Pharm. Anal. Acta"},{"key":"10.1016\/j.jpba.2023.115633_bib25","unstructured":"European Medicines Agency, Guideline on Bioanalytical Method Validation, 2011. \u3008www.ema.europa.eu\/contact\u3009 (Accessed July 29, 2023)."},{"issue":"5","key":"10.1016\/j.jpba.2023.115633_bib26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0731-7085(99)00079-5","article-title":"Characterization of a technique for rapid pharmacokinetic studies of multiple co-eluting compounds by LC\/MS\/MS","volume":"20","author":"Tong","year":"1999","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115633_bib27","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Bioanalytical method validation: guidance for industry, Biopharmaceutics, 2018. \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry\u3009 (Accessed July 29, 2023)."},{"key":"10.1016\/j.jpba.2023.115633_bib28","series-title":"Handbook of LC\u2010MS Bioanalysis: Best Practices, Experimental Protocols, and Regulations","first-page":"297","article-title":"Chapter 23: LC-MS bioanalysis of drugs in tissue samples","author":"Gao","year":"2013"},{"key":"10.1016\/j.jpba.2023.115633_bib29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jchromb.2005.11.009","article-title":"Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis","volume":"830","author":"Matuszewski","year":"2006","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2023.115633_bib30","series-title":"Worldwide Wound Healing \u2013 Innovation in Natural and Conventional Methods","article-title":"Chapter 7: placental cells and tissues: the transformative rise in advanced wound care","author":"Lim","year":"2016"},{"key":"10.1016\/j.jpba.2023.115633_bib31","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2165\/00003495-200565130-00008","article-title":"Sulfasalazine: a review of its use in the management of rheumatoid arthritis","volume":"65","author":"Plosker","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2023.115633_bib32","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2165\/00003088-197601060-00002","article-title":"Clinical pharmacokinetics of sulphasalazine","volume":"1","author":"Das","year":"1976","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2023.115633_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jat\/33.5.243","article-title":"Simultaneous quantification of methadone, cocaine, opiates, and metabolites in human placenta by liquid chromatography-mass spectrometry","author":"De Castro","year":"2009","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.jpba.2023.115633_bib34","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/dta.2381","article-title":"Development and validation of an LC-MS\/MS method for the determination of nicotine and its metabolites in placenta and umbilical cord","volume":"10","author":"Paniagua-Gonz\u00e1lez","year":"2018","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jpba.2023.115633_bib35","series-title":"Sample Preparation in LC-MS Bioanalysis","first-page":"201","article-title":"Tissue sample preparation in LC-MS bioanalysis","author":"Gao","year":"2019"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523004028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523004028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:32:50Z","timestamp":1760002370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523004028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":35,"alternative-id":["S0731708523004028"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115633","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An LC-MS\/MS method for the simultaneous quantitation of sulfasalazine and sulfapyridine in human placenta","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115633"}}